Skip to main content
SpringerLink
Log in

Medical Management of Patients with Refractory Carcinoma In Situ of the Bladder

  • Therapy in Practice
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Bladder cancer is a common genitourinary malignancy and carcinoma in situ (CIS) of the bladder exists as a potentially aggressive variant of the superficial form of the disease. Treatment must reflect the unpredictable nature of this disease entity. In 1976, the use of intravesical Bacillus Calmette-Guerin (BCG) was described for the management of early stage bladder cancer. A subsequent report demonstrated efficacy in a cohort of patients with CIS of the bladder. Since this time, intravesical BCG has been recognised as the initial therapy for CIS of the bladder. Although a 6-week treatment with intravesical BCG has been established as standard therapy in patients with CIS, there has been no consensus as to the subsequent treatment for patients in the setting of failure to initial management with BCG. In addition, a number of reports have demonstrated an increased potential of adverse effects after repeated treatment with intravesical BCG.

A variety of alternative immunological and chemotherapeutic agents have been developed in response to the limitations of BCG for patients with refractory CIS of the bladder. At present, valrubicin remains the only agent that is approved by the US Food and Drug Administration for the specific indication of CIS of the bladder unresponsive to intravesical BCG. Although these agents appear promising, the most efficacious therapy remains to be determined. The specific treatment protocol for refractory CIS of the bladder remains elusive. It is ultimately the combined decision of the clinician and patient to determine which course of management is most beneficial.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Similar content being viewed by others

Chapter © 2016

References

  1. Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1999. Cancer J Clin 1999; 49: 8–31

    Article  CAS  Google Scholar 

  2. Alexandroff AB, Jackson AM, O’Donnell MA, et al. BCG immunotherapy of bladder cancer: 20 years on. Lancet 1999; 353: 1689–94

    Article  PubMed  CAS  Google Scholar 

  3. Ismail MT, Lattime ED, Gomella LG. Current management of superficial bladder cancer: BCG and beyond. Monogr Urol 1998; 33–55

    Google Scholar 

  4. Koss LG, Tiamson EM, Robbins MA. Mapping cancerous and precancerous bladder changes: a study of the urothelium in ten surgically removed bladders. JAMA 1974; 227: 281–6

    Article  PubMed  CAS  Google Scholar 

  5. Soto EA, Friedell GH, Tiltman AJ. Bladder cancer seen in giant histologic sections. Cancer 1977; 39: 447–55

    Article  PubMed  CAS  Google Scholar 

  6. Melicow MM. Histological study of vesical urothelium intervening between gross neoplasms in total cystectomy. J Urol 1952; 68: 261–79

    PubMed  CAS  Google Scholar 

  7. Melicow MM, Hollowell JW. Intraurothelial cancer: carcinoma in situ, Bowen’s disease of urinary system: discussion of 30 cases. J Urol 1952; 68: 763–73

    PubMed  CAS  Google Scholar 

  8. Riddle PR, Chisholm GD, Trott PA, et al. Flat carcinoma in situ of bladder. Br J Urol 1975; 47: 829–33

    Article  PubMed  CAS  Google Scholar 

  9. Lamm DL. Carcinoma in situ. Urol Clin North Am 1992; 19: 499–508

    PubMed  CAS  Google Scholar 

  10. Lamm DL, Blummenstein BA, Crawford ED, et al. A randomized trial of intravesical doxorubicin and immunotherapy with Bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med 1991; 325: 1205–9

    Article  PubMed  CAS  Google Scholar 

  11. Lamm DL. BCG immuotherapy for transitional-cell carcinoma in situ of the bladder. Oncology (Huntingt) 1995; 9: 947–52

    CAS  Google Scholar 

  12. Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Cal-mette-Guerin in the treatment of superficial bladder tumors. J Urol 1976; 116: 180–3

    PubMed  CAS  Google Scholar 

  13. Harland SJ, Charig CR, Highman W, et al. Outcome in carcinoma in situ of bladder treated with intravesical bacille Cal-mette-Guerin. Br J Urol 1992; 70: 271–5

    PubMed  CAS  Google Scholar 

  14. De Jager R, Guinan P, Lamm D, et al. Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette-Guerin: overview analysis of six phase II clinical trials. Urology 1991; 38: 507–13

    Article  PubMed  Google Scholar 

  15. Jakse G, Hall R, Bono A, et al. BCG treatment in Tis of the urinary bladder: results of the EORTC protocol 30861. Prog Clin Biol Res 1992; 378: 69–74

    PubMed  CAS  Google Scholar 

  16. Talic RF, Hargreave TB, Bishop MC, et al. Intravesical Evans bacille Calmette-Guerin for carcinoma in situ of the urinary bladder. Scottish Urological Oncology Group. Br J Urol 1994; 73: 645–8

    Article  PubMed  CAS  Google Scholar 

  17. Akaza H, Hinotsu S, Aso Y, et al. Bacillus Calmette-Guerin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Cancer 1995; 75: 552–9

    Article  PubMed  CAS  Google Scholar 

  18. Nadler RB, Catalona WJ, Hudson MA, et al. Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy. J. Urol 1994; 152: 367–73

    PubMed  CAS  Google Scholar 

  19. Herr HW, Pinsky CM, Whitmore Jr WF, et al. Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder. J Urol 1986; 135: 265–7

    PubMed  CAS  Google Scholar 

  20. Herr HW, Wartinger DD, Fair WR, et al. Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year follow-up. J Urol 1992; 147: 1020–3

    PubMed  CAS  Google Scholar 

  21. Cookson MS, Herr HW, Zhang Z-F, et al. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997; 158: 627

    Article  Google Scholar 

  22. Herr HW, Laudone VP, Badalament RA, et al. Bacillus Cal-mette-Guerin therapy alters the progression of superficial bladder cancer. J Clin Oncol 1988; 6: 1450–5

    PubMed  CAS  Google Scholar 

  23. Hudson MA, Herr HW. Carcinoma in situ of the bladder. J Urol 1995; 153 (3 Pt 1): 564–72

    Article  PubMed  CAS  Google Scholar 

  24. Jakse, G. BCG for carcinoma in situ. Eur Urol 1992; 21Suppl. 2.: 30–4

    PubMed  Google Scholar 

  25. Lamm DL. Optimal BCG treatment of superficial bladder cancer as defined by American trials. Eur Urol 1992; 21Suppl. 2: 12–6

    PubMed  Google Scholar 

  26. Haaff EO, Dresner SM, Ratliff TL, et al. Two courses of intravesical bacillus Calmette-Guerin for transitional cell carci-noma of the bladder. J Urol 1986; 136: 820–4

    PubMed  CAS  Google Scholar 

  27. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000; 163: 1124–9

    Article  PubMed  CAS  Google Scholar 

  28. Reijke TM, De Boer EC, Kurth KH, et al. Urinary interleukin-2 monitoring during prolonged bacillus Calmette-Guerin treatment: can it predict the optimal number of instillations? J Urol 1999; 161: 67–71

    Article  PubMed  Google Scholar 

  29. De Boer EC, DeJong WH, Steerenberg PA, et al. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6 and TNF during intravesical immunotherapy with bacillus Calmette-Guerin in superficial bladder cancer. Cancer Immunol Immunother 1991; 34: 306–12

    Article  Google Scholar 

  30. El-Demiry MIM, Smith G, Ritchie AWS, et al. Local immune responses after intravesical BCG treatment for carcinoma in situ. Br J Urol 1987; 60: 543–8

    Article  PubMed  CAS  Google Scholar 

  31. Coplen DE, Marcus MD, Myers JA, et al. Long-term follow up of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor. J Urol 1990; 144: 652–7

    PubMed  CAS  Google Scholar 

  32. Merz VW, Marth D, Kraft R, et al. Analysis of early failures after intravesical instillation therapy with bacille Calmete-Guerin for carcinoma in situ of the bladder. Br J Urol 1995; 75: 180–4

    Article  PubMed  CAS  Google Scholar 

  33. Friedell HG, Bell JR, Burney SW, et al. Histopathology and classification of urinary bladder carcinoma. Urol Clin North Am 1976; 3: 53–70

    PubMed  CAS  Google Scholar 

  34. Kaubisch S, Lum BL, Reese J, et al. Stage T1 bladder cancer: grade is primary determinant for risk of muscle invasion. J Urol 1991; 146: 28–31

    PubMed  CAS  Google Scholar 

  35. Hillyard Jr RW, Ladaga L, Schellhammer PF. Superficial transitional cell carcinoma of the bladder associated with mucosal involvement of the prostatic urethra:results of treatment with intravesical bacillus Calmette-Guerin. J Urol 1988; 139: 290–3

    PubMed  Google Scholar 

  36. Herr HW, Badalament RA, Amato DA, et al. Superficialbladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J Urol 1989; 141: 22–9

    PubMed  CAS  Google Scholar 

  37. Klein EA, Rogatko A, Herr HW. Management of local bacillus Calmette-Guerin failures in superficial bladder cancer. J Urol 1992; 147: 601–5

    PubMed  CAS  Google Scholar 

  38. Herr HW. When is a cystectomy necessary in carcinoma in situ? Therapeutic progress in urological cancers. Prog Clin Biol Res 1989; 373: 511–5

    Google Scholar 

  39. Van Gils-Gielen RJM, Debruyne FMJ, Witjes WPJ, et al. Risk factors in carcinoma in situ of the urinary bladder. Urology 1994; 45: 581

    Article  Google Scholar 

  40. Farrow GM, Utz DC, Rife CC, et al. Clinical observations on sixty-nine cases of in situ carcinoma of the urinary bladder. Cancer Res 1977; 37 (8 Pt 2): 2794–8

    PubMed  CAS  Google Scholar 

  41. Bretton PR, Herr HW, Whitmore Jr WF, et al. Intravesical bacillus Calmette-Guerin therapy for in situ transitional cell carcinoma involving the prostatic urethra. J Urol 1989; 141: 853–6

    PubMed  CAS  Google Scholar 

  42. Solsona E, Iborra I, Ricos JV, et al. Extravesical involvement in patients with bladder carcinoma in situ: biological and therapy implications. J Urol 1996; 155: 895–9

    Article  PubMed  CAS  Google Scholar 

  43. Pagano F, Bassi P, Galetti TP, et al. Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J Urol 1991; 145: 45–50

    PubMed  CAS  Google Scholar 

  44. Amling CL, Thrasher JB, Frazier HA, et al. Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J Urol 1994; 151: 31–5

    PubMed  CAS  Google Scholar 

  45. Hudson MA, Ratliff TL, Gillen DP, et al. Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial. J Urol 1987; 138: 295–8

    PubMed  CAS  Google Scholar 

  46. Brosman SA. The use of bacillus Calmette-Guerin in the therapy of bladder carcinoma in situ. J Urol 1985; 134: 36–9

    PubMed  CAS  Google Scholar 

  47. Catalona WJ, Hudson MA, Gillen DP, et al. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol 1987; 137: 220–4

    PubMed  CAS  Google Scholar 

  48. Lamm DL, van der Meijden APM, Morales A, et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 1992; 147: 596–600

    PubMed  CAS  Google Scholar 

  49. Lamm DL, Steg A, Boccon-Gibod L, et al. Complications of bacillus Calmette-Guerin immunotherapy: review of 2602 patients and comparison of chemotherapy complications. Prog Clin Biol Res 1989; 310: 335–55

    PubMed  CAS  Google Scholar 

  50. Rawls WH, Lamm DL, Lowe BA, et al. Fatal sepsis following intravesical bacillus Calmette-Guerin administration for bladder cancer. J Urol 1990; 144: 1328–30

    PubMed  CAS  Google Scholar 

  51. Deresiewicz RL, Stone RM, Aster JC. Fatal disseminated mycobacterial infection following intravesical bacillus Cal-mette-Guerin. J Urol 1990; 144: 1331–3

    PubMed  CAS  Google Scholar 

  52. Kim JC, Steinberg GD. The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder. J Urol 2001; 165: 745–56

    Article  PubMed  CAS  Google Scholar 

  53. Sarosdy MF, Manyak MJ, Sagalowsky AI, et al. Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guerin. Urology 1998; 51: 226–31

    Article  PubMed  CAS  Google Scholar 

  54. Sarosdy MF, Lamm DL, Williams RD, et al. Phase I trial of oral bropirimine in superficial bladder cancer. J Urol 1992; 147: 31–3

    PubMed  CAS  Google Scholar 

  55. Sarosdy MF, Lowe BA, Schellhammer PF, et al. Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial. Urology 1996; 48: 21–7

    Article  PubMed  CAS  Google Scholar 

  56. Glashan RW. A randomized controlled study of intravesical α-2b-interferon in carcinoma in situ of the bladder. J Urol 1990; 144: 658–61

    PubMed  CAS  Google Scholar 

  57. Williams RD, Gleason DM, Smith AY, et al. Pilot study of intravesical alfa-2b interferon for treatment of bladder carci-noma in situ following BCG failure [abstract 735]. J Urol 1996; 155 Pt 2: 494A

    Article  Google Scholar 

  58. Nseyo UO, Shumaker B, Klein EA, et al. Photodynamic therapy using porfirmer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder. Bladder Photofrin Study Group. J Urol 1998; 160: 39–44

    Article  PubMed  CAS  Google Scholar 

  59. Greenberg RE, Bahnson RR, Wood D, et al. Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder. Urology 1997; 49: 471–5

    Article  PubMed  CAS  Google Scholar 

  60. Steinberg GD, Bahnson R, Brosman S, et al. Efficacy and safety of valrubicin in the treatment of BCG-refractory carcinoma in situ of the bladder. J Urol2000; 163: 761–7

    Article  PubMed  CAS  Google Scholar 

  61. Torti FM, Shortliffe LD, Williams RD, et al. Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study. J Clin Oncol 1988; 6: 476–83

    PubMed  CAS  Google Scholar 

  62. Belldegrun AS, Franklin JR, O’Donnell MA, et al. Superficial bladder cancer: the role of interferon-alpha. J Urol 1998; 159: 1793–801

    Article  PubMed  CAS  Google Scholar 

  63. Pryor K, Russell P, Stricker P, et al. Antiproliferative effects of bacillus Calmette-Guerin and interferon alpha 2b on human bladder cancer cells. Cancer Immunol Immunother 1995; 41: 309–16

    Article  PubMed  CAS  Google Scholar 

  64. Stricker P, Pryor K, Nicholson T, et al. Bacillus Calmette-Gue-rin plus intravesical interferon alpha-2b in patients with superficial bladder cancer. Urology 1996; 48: 957–61

    Article  PubMed  CAS  Google Scholar 

  65. Bercovich E, Deriu M, Manferrari R, et al. BCG vs. BCG plus recombinant alpha-interferon 2b in superficial tumors of the bladder [in Italian]. Arch Ital Urol Androl 1995; 67: 257–60

    PubMed  CAS  Google Scholar 

  66. O’Donnell MA, Downs TM, DeWolf WC. Co-administration of interferon-alpha 2b with low dose BCG is effective in patients with superficial bladder cancer previously failing BCG alone [abstract 676]. J Urol Suppl 2000; 163: 152

    Google Scholar 

  67. Baselli EC, Greenberg RE. Intravesical therapy for superficial bladder cancer. Oncology (Huntingt) 2000; 14: 719–29

    CAS  Google Scholar 

  68. Prout Jr GR, Lin CW, Benson Jr R, et al. Photodynamic therapy with hematoporphyrin derivative in the treatment of superficial transitional-cell carcinoma of the bladder. N Engl J Med 1987; 317: 1251–5

    Article  PubMed  Google Scholar 

  69. Jocham D, Beer M, Baumgartner R, et al. Long-term experience with integral photodynamic therapy of TIS bladder carcinoma. Ciba Found Symp 1989; 146: 198–205

    PubMed  CAS  Google Scholar 

  70. D’Hallewin MA, Baert L. Long-term results of whole bladder wall photodynamic therapy for carcinoma-in-situ of the bladder. Urology 1995; 45: 763–7

    Article  PubMed  Google Scholar 

  71. Kriegmair M, Zaak D, Hofstetter AG. et al. Transurethral resection (TUR) of bladder cancer controlled by 5-aminolevulonic acid induced fluorescence endoscopy (AFE) versus white light endoscopy [abstract 664]. J Urol 2000; 163 Pt 2: 149

    Article  Google Scholar 

  72. Lamm DL. Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 1992; 19: 573–80

    PubMed  CAS  Google Scholar 

  73. Pagano F, Bassi P, Milani C, et al. A low dose bacillus Calm-ette-Guerin regimen in superficial bladder cancer therapy: is it effective? J Urol 1991; 146: 32–5

    PubMed  CAS  Google Scholar 

  74. Israel M, Idriss JM, Koseki Y, et al. Comparative effects of adriamycin and DNA-non-binding analogues on DNA, RNA, and protein synthesis in vitro. Cancer Chemother Pharmacol 1987; 20: 277–84

    Article  PubMed  CAS  Google Scholar 

  75. Krishan A, Dutt K, Israel M, et al. Comparative effects of adri-amycin and N-trifluoroacetyladriamycin-14-valerate on cell kinetics, chromosomal damage, and macromolecular synthesis in vitro. Cancer Res 1981; 41: 2745–50

    PubMed  CAS  Google Scholar 

  76. Sweatman TW, Parker RF, Israel M. Pharmacologic rationale for intravesical N-trifluoroacetyladriamycin14-valerate (AD 32): a preclinical study. Cancer Chemother Pharmacol 1991; 28: 1–6

    Article  PubMed  CAS  Google Scholar 

  77. Henderson IC, Billingham M, Israel M, et al. Comparative cardiotoxicity studies with adriamycin (ADR) and AD 32 in rabbits [abstract]. Proc Am Assoc Cancer Res 1978; 19: 158

    Google Scholar 

  78. Bahnson R, Brosman S, Greenberg R, et al. Multicenter efficacy and safety study of intravesical AD 32 (Valrubicin) in the treatment of patients with refractory bladder carcinoma in situ [abstract 551]. J Urol 1998; 159: 145

    Article  Google Scholar 

  79. Onrust SV, Lamb HM. Valrubicin. Drugs Aging 1999; 15: 69–75

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Urology, Department of Surgery, University of Chicago, Pritzker School of Medicine, Chicago, Illinois, USA

    James C. Kim &  Gary D. Steinberg

Authors
  1. James C. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gary D. Steinberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gary D. Steinberg.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, J.C., Steinberg, G.D. Medical Management of Patients with Refractory Carcinoma In Situ of the Bladder. Drugs & Aging 18, 335–344 (2001). https://doi.org/10.2165/00002512-200118050-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200118050-00004

Keywords

Search

Navigation